Neuphoria Responds to Lynx1's Misleading Campaign, Urges Stockholders to Vote for Experienced Nominees

Neuphoria Therapeutics responded to Lynx1's allegations, stating that Lynx1's claims are false and misleading. Lynx1 had expressed support for Neuphoria's board and encouraged the company to use its ATM program, but later nominated two directors and proposed a cash acquisition. Neuphoria believes Lynx1's actions are a campaign of deception and distraction to deflect attention from its own limitations. Neuphoria urges stockholders to vote for its nominees Peter Miles Davies and David Wilson and withhold votes on Lynx1's nominees.